S. T. Harris

发表

Bone mineral content in early-postmenopausal and postmenopausal osteoporotic women: comparison of measurement methods.

H. Genant, B. Ettinger, W. Reinbold, 1986, Radiology.

In Vivo Assessment of Architecture and Micro-Finite Element Analysis Derived Indices of Mechanical Properties of Trabecular Bone in the Radius

S. Majumdar, H. Genant, B. van Rietbergen, 2002, Osteoporosis International.

Noninvasive assessment of bone mineral and structure: State of the art

S. Majumdar, M. Jergas, H. Genant, 1996, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

Classification Algorithms for Hip Fracture Prediction Based on Recursive Partitioning Methods

H. Genant, M. Hochberg, Ying Lu, 2004, Medical decision making : an international journal of the Society for Medical Decision Making.

Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group.

H K Genant, Jacques P. Brown, H. Genant, 1999, JAMA.

AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS/AMERICAN COLLEGE OF ENDOCRINOLOGY CLINICAL PRACTICE GUIDELINES FOR THE DIAGNOSIS AND TREATMENT OF POSTMENOPAUSAL OSTEOPOROSIS-2020 UPDATE.

N. Watts, Rachel Pessah-Pollack, N. Binkley, 2020, Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists.

Bisphosphonates and osteonecrosis of the jaw.

N. Watts, J. Bilezikian, S. Greenspan, 2006, Annals of internal medicine.

Frequency of discontinuation of injectable osteoporosis therapies in US patients over 2 years

E. Lewiecki, S. T. Harris, A. Modi, 2017, Osteoporosis International.

Western Osteoporosis Alliance Clinical Practice Series: Evaluating the Balance of Benefits and Risks of Long-Term Osteoporosis Therapies.

P. Miller, M. McClung, E. Lewiecki, 2017, The American journal of medicine.

Monitoring bone resorption in early postmenopausal women by an immunoassay for cross‐linked collagen peptides in urine

H. Genant, D. Eyre, B. Gertz, 1994, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

American Association of Clinical Endocrinologists Medical Guidelines for Clinical Practice for the diagnosis and treatment of postmenopausal osteoporosis: executive summary of recommendations.

N. Watts, J. Bilezikian, M. Kleerekoper, 2010, Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists.

Bisphosphonate therapy for osteoporosis: benefits, risks, and drug holiday.

D. Bauer, P. Miller, M. McClung, 2013, The American journal of medicine.

Current and emerging therapies for osteoporosis.

S. T. Harris, N. Mitchner, 2009, The Journal of family practice.

Risk of Severe Gastrointestinal Events in Women Treated with Monthly Ibandronate or Weekly Alendronate and Risedronate

S. Silverman, Liping Huang, S. T. Harris, 2009, The Annals of pharmacotherapy.

Risk of fracture in women treated with monthly oral ibandronate or weekly bisphosphonates: the eValuation of IBandronate Efficacy (VIBE) database fracture study.

J. Reginster, S. Silverman, C. Barr, 2009, Bone.

Clinical use of teriparatide in the real world: initial insights.

J. Bilezikian, P. Miller, S. T. Harris, 2004, Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists.

Bisphosphonates for the Treatment of Postmenopausal Osteoporosis: Clinical Studies of Etidronate and Alendronate

S. T. Harris, 2001, Osteoporosis International.

Effect of combined risedronate and hormone replacement therapies on bone mineral density in postmenopausal women.

A. Chines, E. Eriksen, S. T. Harris, 2001, The Journal of clinical endocrinology and metabolism.

Addition of alendronate to ongoing hormone replacement therapy in the treatment of osteoporosis: a randomized, controlled clinical trial.

R. Lindsay, B. Walsh, R. Lobo, 1999, The Journal of clinical endocrinology and metabolism.

Clinical Application of Bone Densitometry

P. Miller, S. T. Harris, 1998 .

The effect of 2 and 3 years of Raloxifene on vertebral and non-vertebral fractures in postmenopausal women with osteoporosis

J. Reginster, R. Eastell, P. Delmas, 1998 .

Diagnosis and Treatment of Osteoporosis Before and After Fracture: A Side-by-Side Analysis of Commercially Insured and Medicare Advantage Osteoporosis Patients.

E. Lewiecki, S. T. Harris, S. Sajjan, 2017, Journal of managed care & specialty pharmacy.

Prevalence and Cost of Subsequent Fractures Among U.S. Patients with an Incident Fracture.

E. Lewiecki, S. T. Harris, S. Sajjan, 2017, Journal of managed care & specialty pharmacy.

Acronyms in bone densitometry

S. Majumdar, H. Genant, K. Engelke, 1992, Osteoporosis International.

Western Osteoporosis Alliance Clinical Practice Series: Treat-to-Target for Osteoporosis.

P. Miller, M. McClung, E. Lewiecki, 2019, The American journal of medicine.

Four-year study of intermittent cyclic etidronate treatment of postmenopausal osteoporosis: three years of blinded therapy followed by one year of open therapy.

H. Genant, N. Watts, R. Jackson, 1993, The American journal of medicine.

Understanding and communicating the benefits and risks of denosumab, raloxifene, and teriparatide for the treatment of osteoporosis.

D. Bauer, P. Miller, M. McClung, 2014, Journal of clinical densitometry : the official journal of the International Society for Clinical Densitometry.

Intermittent cyclical etidronate treatment of postmenopausal osteoporosis.

W. Mysiw, H. Genant, N. Watts, 1990, The New England journal of medicine.

The effect of short term treatment with alendronate on vertebral density and biochemical markers of bone remodeling in early postmenopausal women.

H. Genant, D. Eyre, B. Gertz, 1993, The Journal of clinical endocrinology and metabolism.

The effects of estrone (Ogen) on spinal bone density of postmenopausal women.

H. Genant, J. Gallagher, H. Genant, 1991, Archives of internal medicine.

Chronic intermittent cyclical administration of tiludronate in postmenopausal osteoporosis: report of two multicenter studies in 2136 patients

H. Genant, J. Eisman, R. Recker, 1998 .

Alendronate treatment of the postmenopausal osteoporotic woman: effect of multiple dosages on bone mass and bone remodeling.

H. Genant, P. Delmas, K. Ensrud, 1995, The American journal of medicine.

The role of osteoanabolic agents in the management of patients with osteoporosis

P. Miller, M. McClung, E. Lewiecki, 2022, Postgraduate medicine.

Progestin antagonism of estrogen stimulated 1,25-dihydroxyvitamin D levels.

S. T. Harris, D. Bikle, B. Halloran, 1992, The Journal of clinical endocrinology and metabolism.

Safety and tolerability of oral daily and intermittent ibandronate are not influenced by age.

D. Felsenberg, P. Miller, S. T. Harris, 2005, The Journal of rheumatology.

An examination of the association between vertebral deformities, physical disabilities and psychosocial problems.

S. Cummings, H. Genant, B. Ettinger, 1988, Maturitas.

AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY CLINICAL PRACTICE GUIDELINES FOR THE DIAGNOSIS AND TREATMENT OF POSTMENOPAUSAL OSTEOPOROSIS - 2016--EXECUTIVE SUMMARY.

N. Watts, M. Kleerekoper, Rachel Pessah-Pollack, 2020, Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists.

Addition of alendronate to ongoing hormone replacement therapy in the treatment of osteoporosis: a randomized, controlled clinical trial.

R. Lindsay, B. Walsh, R. Lobo, 1999, The Journal of clinical endocrinology and metabolism.

Short-term effect of alendronate on bone mass and bone remodeling in postmenopausal women

S. T. Harris, C. Chesnut, 1993, Osteoporosis International.

Improved mineral balance and skeletal metabolism in postmenopausal women treated with potassium bicarbonate.

R. Morris, J. Ottaway, A. Sebastian, 1994, The New England journal of medicine.

Dose-response relationships for alendronate treatment in osteoporotic elderly women. Alendronate Elderly Osteoporosis Study Centers.

D. Kimmel, R. Weinstein, W. Polvino, 1997, The Journal of clinical endocrinology and metabolism.

Relationship Between Gastrointestinal Events and Compliance With Osteoporosis Therapy: An Administrative Claims Analysis of the US Managed Care Population.

S. T. Harris, A. Modi, S. Sajjan, 2016, Clinical therapeutics.

American Association of Clinical Endocrinologists Medical Guidelines for Clinical Practice for the diagnosis and treatment of postmenopausal osteoporosis.

N. Watts, J. Bilezikian, M. Kleerekoper, 2010, Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists.

Parathyroid hormone and teriparatide for the treatment of osteoporosis: a review of the evidence and suggested guidelines for its use.

D. Bauer, D. Dempster, E. Orwoll, 2005, Endocrine reviews.

Proceedings of the 2017 Santa Fe Bone Symposium: Insights and Emerging Concepts in the Management of Osteoporosis.

C. Gordon, J. Bilezikian, P. Miller, 2018, Journal of clinical densitometry : the official journal of the International Society for Clinical Densitometry.

Efficacy of raloxifene on vertebral fracture risk reduction in postmenopausal women with osteoporosis: four-year results from a randomized clinical trial.

J. Reginster, H. Genant, R. Eastell, 2002, The Journal of clinical endocrinology and metabolism.

Dose-Response Relationships for Alendronate Treatment in Osteoporotic Elderly Women

D. Kimmel, R. Weinstein, W. Polvino, 1997 .

Secondary hyperparathyroidism associated with dichloromethane diphosphonate treatment of Paget's disease.

G. Segre, J. Potts, R. Neer, 1982, The Journal of clinical endocrinology and metabolism.

Cyclical etidronate in the treatment of postmenopausal osteoporosis: efficacy and safety after seven years of treatment.

H. Genant, N. Watts, P. Miller, 1997, The American journal of medicine.

The clinical diagnosis of osteoporosis: a position statement from the National Bone Health Alliance Working Group

S. Silverman, N. Watts, S. Khosla, 2014, Osteoporosis International.

AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY CLINICAL PRACTICE GUIDELINES FOR THE DIAGNOSIS AND TREATMENT OF POSTMENOPAUSAL OSTEOPOROSIS - 2016.

N. Watts, M. Kleerekoper, Rachel Pessah-Pollack, 2016, Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists.

Vertebral Fractures: Clinical Importance and Management.

D. Bauer, J. Schousboe, P. Miller, 2016, The American journal of medicine.

Treatment of Painful Osteoporotic Vertebral Fractures with Percutaneous Vertebroplasty or Kyphoplasty

H. Genant, N. Watts, S. T. Harris, 2001, Osteoporosis International.

Appropriate use of bone densitometry.

C C Glueer, H K Genant, J E Block, 1989, Radiology.

Before the breaking point: reducing the risk of osteoporotic fracture.

A. Singer, S. T. Harris, D. Forstein, 2013, The Journal of the American Osteopathic Association.

Adherence to bisphosphonate therapy and fracture rates in osteoporotic women: relationship to vertebral and nonvertebral fractures from 2 US claims databases.

S. Silverman, J. N. Arvesen, E. Siris, 2006, Mayo Clinic proceedings.

Assessment of vertebral bone mineral density using volumetric quantitative CT.

H K Genant, J. Li, H. Genant, 1999, Journal of computer assisted tomography.

Management of osteoporosis in postmenopausal women: 2006 position statement of The North American Menopause Society

J. Manson, S. Silverman, V. Henderson, 2006, Menopause.

AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS/AMERICAN COLLEGE OF ENDOCRINOLOGY CLINICAL PRACTICE GUIDELINES FOR THE DIAGNOSIS AND TREATMENT OF POSTMENOPAUSAL OSTEOPOROSIS- 2020 UPDATE EXECUTIVE SUMMARY.

N. Watts, Rachel Pessah-Pollack, N. Binkley, 2020, Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists.

Effect of Combined Risedronate and Hormone Replacement Therapies on Bone Mineral Density in Postmenopausal Women

A. Chines, E. Eriksen, S. T. Harris, 2001 .

Bone mineral density in patients with alopecia areata treated with long-term intralesional corticosteroids.

S. T. Harris, V. Price, A. Samrao, 2013, Journal of drugs in dermatology : JDD.

Ibandronate produces significant, similar antifracture efficacy in North American and European women: new clinical findings from BONE

N. Watts, R. Recker, P. Miller, 2005, Current medical research and opinion.

The effects of raloxifene on incident vertebral fractures in postmenopausal women with osteoporosis : 4-year results from the MORE trial

J. Reginster, H. Genant, R. Eastell, 2000 .

Ibandronate and the risk of non-vertebral and clinical fractures in women with postmenopausal osteoporosis: results of a meta-analysis of phase III studies*

P. Miller, S. T. Harris, W. A. Blumentals, 2008, Current medical research and opinion.

N. Watts, Rachel Pessah-Pollack, N. Binkley, 2020, Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists.

Reducing the Risk of Osteoporotic Fracture

A. Singer, S. T. Harris, D. Forstein, 2013 .

Skeletal Effects of Raloxifene After 8 Years: Results from the Continuing Outcomes Relevant to Evista (CORE) Study

S. Cummings, A. Díez-Pérez, R. Eastell, 2005, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

OSTEOPOROSIS: HARD FACTS ABOUT BONES

S. T. Harris, Steven T. Harris, 2002 .

Increments in bone mineral density of the lumbar spine and hip and suppression of bone turnover are maintained after discontinuation of alendronate in postmenopausal women.

H. Genant, K. Ensrud, M. McClung, 1997, The American journal of medicine.

Prevention of nonvertebral fractures by alendronate. A meta-analysis. Alendronate Osteoporosis Treatment Study Groups.

Ego Seeman, Deborah R. Shapiro, Leonard Oppenheimer, 1997, JAMA.

Assessing fracture risk and effects of osteoporosis drugs: bone mineral density and beyond.

D. Bauer, D. Dempster, M. McClung, 2009, The American journal of medicine.

Quantitative computed tomography: Update 1987

C C Glueer, H K Genant, J E Block, 1987, Calcified Tissue International.

Two-year efficacy and tolerability of risedronate once a week for the treatment of women with postmenopausal osteoporosis

Jacques P. Brown, N. Watts, A. Chines, 2004, Current medical research and opinion.

Spinal bone mineral density measured with quantitative CT: effect of region of interest, vertebral level, and technique.

C C Glüer, H K Genant, J E Block, 1990, Radiology.

History of etidronate.

W. Mysiw, H. Genant, N. Watts, 2020, Bone.

Progression of Efficacy with Ibandronate

M. Zaidi, S. Epstein, S. T. Harris, 2007, Annals of the New York Academy of Sciences.

Cyclical etidronate treatment of postmenopausal osteoporosis: 4 year experience

H. Genant, N. Watts, P. Miller, 1992 .

Preventing nonvertebral osteoporotic fractures with extended-interval bisphosphonates: regimen selection and clinical application.

S. T. Harris, R. Cole, 2009, Medscape journal of medicine.

Bisphosphonates: safety and efficacy in the treatment and prevention of osteoporosis.

N. Watts, E. Orwoll, P. Miller, 2000, American family physician.

A randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis: the prevent recurrence of osteoporotic fractures study. PROOF Study Group.

D. Kiel, S. Silverman, H. Genant, 2000, The American journal of medicine.

AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS/ AMERICAN COLLEGE OF ENDOCRINOLOGY CLINICAL PRACTICE GUIDELINES FOR THE DIAGNOSIS AND TREATMENT OF POSTMENOPAUSAL OSTEOPOROSIS- 2020 UPDATE.

N. Watts, Rachel Pessah-Pollack, N. Binkley, 2021, Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists.

Improved mineral balance and skeletal metabolism in postmenopausal women treated with potassium bicarbonate.

R. Morris, A. Sebastian, S. T. Harris, 1994, The New England journal of medicine.

Uniform terminology and corresponding abbreviation for Dual X-ray Absorptiometry (DXA)

S. Majumdar, H. Genant, C. V. van Kuijk, 1992, Bone.

Medicines and bone loss.

J. Bollerslev, S. T. Harris, B. Leder, 2013, The Journal of clinical endocrinology and metabolism.

American Association of Clinical Endocrinologists Medical Guidelines for Clinical Practice for the diagnosis and treatment of postmenopausal osteoporosis.

N. Watts, J. Bilezikian, M. Kleerekoper, 2010, Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists.

AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY CLINICAL PRACTICE GUIDELINES FOR THE DIAGNOSIS AND TREATMENT OF POSTMENOPAUSAL OSTEOPOROSIS - 2016.

N. Watts, M. Kleerekoper, Rachel Pessah-Pollack, 2016, Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists.